Exai Bio, Quantum Leap Healthcare Collaborative Expand Participation in RNA Liquid Biopsy Trial
The collaborators are using Exai's oncRNA-based liquid biopsy tech in predicting clinical outcomes and treatment response in the I-SPY 2 trial.
The company is assessing a variety of applications, including cancer early detection, using algorithms to analyze orphan noncoding RNA in blood.
The company's adaptive low-resource testing technology requires no instrumentation and limited equipment, making it adaptable to settings without clinical lab infrastructure.
The firm recently published a study describing three assays for prostate cancer and reporting their sensitivity and specificity in case-control cohort.
Researchers have demonstrated that they can detect more miRNAs, as well as other small RNA molecules, by sequencing these samples rather than using microarrays.